MycoBiomDB – Record Details (MyCo_5494)

Biomarker Record Details

Database ID: MyCo_5494
DB IDMyCo_5494
TitleAntifungal treatment affects the laboratory diagnosis of invasive aspergillosis
Year2011
PMID22049217
Fungal Diseases involvedInvasive aspergillosis
Associated Medical ConditionNone
GenusAspergillus
Speciesfumigatus
OrganismAspergillus fumigatus
Ethical StatementNone
Site of InfectionNone
Opportunistic invasiveInvasive
Sample typeBody fluid
Sample sourceSerum
Host GroupAnimal
Host Common nameMice
Host Scientific nameMus musculus
Biomarker Name18S rRNA gene + posaconazole
Biomarker Full Name18S rRNA gene + posaconazole
Biomarker TypeDiagnostic
BiomoleculeGene
Geographical LocationUK
CohortA standardised rat inhalation model of aspergillosis was used. Briefly, each animal was immunosuppressed using 75 mg/kg cyclophosphamide and 16 mg/kg depo-medrone. Prophylactic antibiotics (baytril 50 ppm) were added to the drinking water throughout the study.
Cohort No.None
Age GroupNone
P Valuep=0.041
SensitivityNone
SpecificityNone
Positive Predictive ValueNone
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismInvasive aspergillosis (IA) remains a major concern in the management of patients undergoing haematopoietic stem cell transplantation. As a result of the acknowledged risk of IA a number of strategies have been developed for the use of anti- fungal agents ranging from prophylaxis,1 via preemptive therapy2 to empiric therapy.3 Despite the availability of a number of new mould active antifungal agents IA continues to have a high mortality rate1 and the diagnosis of IA remains problematical4 with many cases not diagnosed until after death.
TechniquePCR
Analysis MethodPCR Based
ELISA kitsNone
Assay DataNone
Validation Techniques usedPCR
Up Regulation Down RegulationPositive
Sequence DataNone
External LinkNone